Shruti Bhat PhD, MBA, Lean Six Sigma Black Belt
  • Home
  • About Shruti
  • Consulting
  • Workshops
  • Patents
  • Articles
    • Case Studies
    • Innovation Portfolio Development & Patents
    • Drugs-in-the- making
    • Culture Change & Business Transformation
    • Operational Excellence, Quality & Continuous Improvement
  • Books
  • Digital
  • Blog
  • Videos
  • Contact

Is Genzyme history?

12/1/2010

0 Comments

 
Here are some highlights from current pharma and clinical research news, views and data.   

Frederick Frank, a leading biotechnology banker and vice chairman of investment advisory firm Peter J. Solomon, said Genzyme Corp (GENZ.O) has no chance of remaining an independent company.

French drugmaker Sanofi-Aventis SA (SASY.PA) has made a hostile tender offer of $18.5 billion, or $69 a share, for the Cambridge, Massachusetts-based maker of drugs for rare diseases. Genzyme has rejected the bid but Sanofi is expected ultimately to prevail.

"Genzyme is history," Frank said at the Reuters Health Summit on Monday. "It's only a question of when and at what price."

Genzyme's shares closed on Monday at $71.06, and Frank said that if a deal were to fall through the stock price would likely fall into the mid-$50 range.

"I would estimate that 40 to 50 percent of the shares are held in the arbitrage community," he said, referring to short-term investors who specialize in takeover targets. "That's a big load to be sold."

Frank, former vice chairman of Lehman Brothers and, until 2009, of Barclays Capital, has advised on countless transactions in the pharmaceuticals and biotech sector.

He said he expects mergers and acquisitions in the space to continue, since big pharmaceuticals companies are eager to acquire products to replace those that are losing patent protection.

But once Genzyme is gone, there will only be a handful of large biotech companies left, including Amgen Inc (AMGN.O), Gilead Sciences Inc (GILD.O) and Biogen Idec Inc (BIIB.O). If and when they too disappear, it is unlikely the industry will see new companies of their ilk emerge, he said.

"Today, venture capitalists are willing to finance a company through mid-stage trials but with the goal of selling it at that point," he said. "You're not going to see a lot of new Amgens or Genentechs."

Genentech, the oldest and second-biggest biotech after Amgen, was fully acquired by Swiss drug-maker Roche Holding AG (ROG.VX) in early 2009.

Still, Frank said acquisitions will depend on valuations. Biogen Idec Inc (BIIB.O), which makes the multiple sclerosis drugs Avonex and Tysabri, has long been considered an acquisition target. But in 2007 the company tried and failed to sell itself.

Frank said he was approached by a big pharmaceuticals company to represent them in a possible purchase of Biogen but he recommended against it.

"On the surface the numbers look very attractive," he said, "but their wonderful drug Tysabri, for a very small group of people, has the potential to kill you."

Tysabri has been linked with PML, a potentially deadly brain infection, and is competing in an ever-more crowded space. Recently U.S. regulators approved the first oral MS drug, Gilenya, made by Novartis AG (NOVN.VX) that is widely expected to become a leading player in the space.

Biogen is working on a test that could potentially screen patients at higher risk for developing PML, but uncertainty remains.

Despite Sanofi's hostile bid for Genzyme, Frank does not expect hostile offers to increase.

"I don't think you'll see a lot of them," he said. "These companies are very management intensive; you do a hostile tender offer, you tend to lose the management."

For big pharmaceuticals companies, a new era is at hand, in which insurance companies are increasingly in the driver's seat, he said.

"In the past, the payer community was not very active; the pharma companies set their prices and their prices were largely paid. Now the focus of power has changed."

No longer can drug companies develop products with only marginal improvements over rival drugs. Payers won't pay, he said.

"We're entering a new world," he said. "Pharma companies are going to spend a lot of time developing first-in-class drugs."

​
Disclaimer- In addition to Terms and Conditions of the blog, the content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
Follow Shruti on Twitter, Facebook, YouTube, LinkedIn
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Shruti Bhat, global leader in business turnaround, operational excellence and continuous improvement

    New Book Released!

    top ten strategic decision-making tools for operational excellence

    Shruti's YouTube Channel ...

    Picture

    Blog Categories

    All
    3D Printing
    5S
    Agile
    Artificial Intelligence
    Automation
    Balanced Score Card
    Biotechnology
    Books
    Business Turnaround
    Case Studies
    Change Management
    Chemical Industry
    CMMI
    Continuous Improvement
    Design Thinking
    Digitalization
    Drug Delivery
    External News Links
    Food Industry
    Hall Of Fame
    Healthcare
    Hoshin Kanri
    HR Development
    Innovation
    ISO
    Just In Time
    Kaizen
    Leadership
    LEAN
    Lean Six Sigma
    Life Sciences
    Machine Learning
    Manufacturing
    Medical Devices
    Mistake Proofing
    Motivational Cards
    Nanotechnology
    Operations
    Packaging
    Patents
    Personal Products
    Process Improvement
    Product Development
    Productivity Increase
    QbD
    Quality Management
    Robotics
    Scrum
    Service Industry
    Six Sigma
    Strategy
    Supply Chain Logistics
    Telecom Industry
    TQM
    Videos
    Voice Of Customer
    Workshops

    Shruti's books...

    Picture
    shruti bhat, business process management, continuous improvement
    kaizen for pharmaceutcials, medical devices and biotech industry book by Dr Shruti Bhat
    Book on Continuous improvement tools by Dr Shruti Bhat
    kaizen for leaders, continuous process improvement tool to increase profit and organizational excellence by shruti bhat
    kaizen, shruti bhat, continuous improvement, quality, operations management
    Picture
    how to overcome challenges of creating effective teams
    how to lead a successful business transformation

    ​Micro-Learning
    ​Partner

    Picture

    Publishing Partner

    fast read books, business management books, health and wellness books, spiritual guidance books, best online book store

    Wellness
    ​Partner

    Picture
© Copyright 1992- 2022 Dr. Shruti Bhat ALL RIGHTS RESERVED.
See Terms and Conditions for details on this site usage.
SHRUTI BHAT, CONTACT
Click to connect.
Created by Macro2Micro Media